Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Проксимальная спинальная мышечная атрофия 5q

Список литературы

  1. Brzustowicz L.M., Lehner T., Castilla et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2 - q13.3. // Nature. 1990. V. 344. P. 540­541.
  2. Burglen L., Lefebvre S., Clermont O. et al. Structure and organization of the human survival motor neuron (SMN) gene. // Genomics. 1996a. V. 32. P. 479-482.
  3. Lorson C.L., Hahnen E., Androphy E.J. et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy // Proc. Natl. Acad. Sci. USA. 1999. V. 96. P. 6307-6311.
  4. Lefebvre S., BurglenL.,Reboullet S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. // Cell. 1995. V.80. P. 155-165.
  5. Harada Y., Sutomo R., Sadewa A.H. et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity // J Neurol. 2002. V. 249(9) P. 1211-1219.
  6. Jedrzejowska M., Milewski M., Zimowski J. et al. Phenotype modifiers of spinal muscular atrophy: the number of SMN2 gene copies, deletion in the NAIP gene and probably gender influence the course of the disease // ActaBiochimicaPolonica. 2009. V. 56. P. 103-108.
  7. Butchbach M.E.R. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. // Front Mol Biosci. 2016 V. 3 P. 7.
  8. Prior T.W., Swoboda K.J., Scott H.D. et al. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2 // Am J Med Genet. 2004. V. 130A. P. 307-310.
  9. Tizzano E., Baiget M. Molecular bases of spinal muscular atrophy: the survival motoneuron gene // Contributions to Science. 2001. V. 2. P. 35-42.
  10. Burghes A. H. M., Beattie C.E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? // Nat Rev Neurosci. 2009 V. 10(8) P. 597­609.
  11. Rossoll W., Bassell G.J. Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. // Results Probl Cell Differ. 2009 V. 48 P. 289-326.
  12. Calucho M., Bernal S., Ahas L. et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. // Neuromuscul Disord. 2018 V. 28(3) P. 208-215.
  13. Bernal S., AHas L., Barcelo M.J. et al. The c.859G>C variant in the SMN2 gene is associated with both type II and III SMA and originates from a common ancestor. // J Med Genet. 2010 V. 47(9) P. 640-2.
  14. Hosseinibarkooie S., Peters M., Torres-Benito L. et al. The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype. // Am J Hum Genet. 2016 V. 99(3) P. 647-665.
  15. Kaczmarek A. Analysis of reduced Neurocalcin delta (NCALD) as a protective modifier in mouse models of Spinal Muscular Atrophy (SMA). // PhD thesis, Universitat zu Koln, Koln, 2016
  16. Janzen E., Mendoza-Ferreira N., Hosseinibarkooie S., et al. (2018). CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis. // Brain. 2018 V. 141(8) P. 2343-2361.
  17. Zheleznyakova GY, Voisin S, Kiselev AV, Sallman Almen M, Xavier MJ, Maretina MA, Tishchenko LI, Fredriksson R, Baranov VS, Schioth HB. Genome-wide analysis shows association of epigenetic changes in regulators of Rab and Rho GTPases with spinal muscular atrophy severity. // Eur. J.Hum. Genet. 2013 V. 21 P. 988-993.
  18. Zheleznyakova, G. Y., Nilsson, E. K., Kiselev, A. V., Maretina, M. A., Tishchenko, L. I., Fredriksson, R., ... & Schioth, H. B. Methylation Levels of SLC23A2 and NCOR2 Genes Correlate with Spinal Muscular Atrophy Severity. // PloS one. 2015 V. 10(3) e0121964.
  19. Maretina M. A., Egorova A. A., Baranov V. S., Kiselev A. V. DYNC1H1 gene methylation correlates with severity of spinal muscular atrophy // Ann. Hum. Genet. 2019 V. 83(2) P. 73-81.
  20. Mercuri E., Finkel R.S., Muntoni F., et al; SMA Care Group. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. // Neuromuscul Disord. 2018 V. 28(2) P. 103-115. doi: 10.1016/j.nmd.2017.11.005
  21. Ogino S., Leonard D.G., Rennert H. et al. Genetic risk assessment in carrier testing for spinal muscular atrophy. // Am J Med Genet. 2002, V. 110 P. 301-07.
  22. Prior T.W., Snyder P.J., Rink B.D. et al.: Newborn and carrier screening for spinal muscular atrophy. // Am J Med Genet A. 2010, V. 152A P. 1605-1607.
  23. Zabnenkova V.V., Dadali E.L., Spiridonova M.G., et al. Spinal muscular atrophy carrier frequency in Russian Federation // ASHG 2016. P. 2476W.
  24. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype // Eur J Paediatr Neurol. 1999. V. 3(2). P. 49-51.
  25. Pearn J.H., Wilson J. Acute Werdnig-Hoffmann disease: acute infantile spinal muscular atrophy. // Arch Dis Child. 1973 V. 48(6) P. 425-430.
  26. Darras B.T., Markowitz J.A., Monani U.R, De Vivo D.C. Neuromuscular Disorders of Infancy, Childhood, and Adolescence (Second Edition) // Academic Press, 2015, P. 117­145
  27. Prior T.W., Leach M.E., Finanger E. Spinal muscular atrophy // In: Adam M.P., Ardinger H.H., Pagon R.A., et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
  28. Russman B.S. Spinal muscular atrophy: clinical classification and disease heterogeneity // J Child Neurol. 2007, V. 22(8). P. 946-951.
  29. Mellies U1, Dohna-Schwake C, Stehling F, Voit T.Sleep disordered breathing in spinal muscular atrophy. //Neuromuscul Disord. 2004 V.14(12)P.797-803.
  30. Федеральные клинические рекомендации (протоколы) по диагностике и лечению спинальных мышечных атрофий у детей.// Авторы: Влодавец Д.В, Харламов Д.А., Артемьева С.Б., Белоусова Е.Д., 2013; 32 стр. http://ulgb3.ru/doc/211218 10-58.pdf
  31. Sproule D.M., Montes J., Montgomery M., et al. Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. // Neuromuscul Disord. 2009 ,V. 19(6) P. 391-6
  32. Chen Y.S., Shih H.H., Chen T.H. et al. Prevalence and risk factors for feeding and swallowing difficulties in spinal muscular atrophy types II and III. // J Pediatr. 2012 V. 160(3) P. 447-451.e1.
  33. Wijngaarde C.A., Veldhoen E.S., van Eijk R.P.A., Stam M.et al. Natural History of Lung Function in Spinal Muscular Atrophy Orphanet.// J Rare Dis 2020 Apr V.10;15(1):P. 88.doi: 10.1186/s13023-020-01367-y.
  34. Fujak A., Raab W., Schuh A. et al. Natural course of scoliosis in proximal spinal muscular atrophy type II and IIIa: descriptive clinical study with retrospective data collection of 126 patients. // BMC Musculoskelet Disord. 2013 V. 14 P. 283.
  35. Kouwenhoven J.W., Van Ommeren P.M., Pruijs H.E., Castelein R.M. Spinal decompensation in neuromuscular disease. // Spine (Phila Pa 1976). 2006 V.31(7) P. E188- 91.
  36. Mazzone E, De Sanctis R, Fanelli L, Bianco F, Main M, van den Hauwe  M, Ash M, de Vries R, Fagoaga Mata J, Schaefer K, D'Amico A, Colia G, Palermo C, Scoto M, Mayhew A, Eagle M, Servais L, Vigo M, Febrer A, Korinthenberg R, Jeukens M, de Viesser M, Totoescu A, Voit T, Bushby K, Muntoni F, Goemans N, Bertini E, Pane M, Mercuri E.Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. //Neuromuscul Disord. 2014, V.24(4) P.347­52. doi: 10.1016/j.nmd.2014.01.003. Epub 2014 Jan 16.
  37. Montes J, McDermott MP, Martens WB, Dunaway S, Glanzman AM, Riley S, Quigley J, Montgomery MJ, Sproule D, Tawil R, Chung WK, Darras BT, De Vivo DC, Kaufmann P, Finkel RS; Muscle Study Group and the Pediatric Neuromuscular Clinical Research Network. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. //Neurology. 2010, V.9;74(10) P.833-8. doi: 10.1212/WNL.0b013e3181d3e308.
  38. Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, Scott C, Pane M, Messina S, Bertini E, Mercuri E, Finkel RS. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. //Neuromuscul Disord. 2010, V.20(3) P.155-61. doi: 10.1016/j.nmd.2009.11.014. Epub 2010 Jan 13.
  39. Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, Salazar R, De Sanctis R, Pasternak A, Glanzman A, Coratti G, Civitello M, Forcina N, Gee R, Duong T, Pane M, Scoto M, Pera MC, Messina S, Tennekoon G, Day JW, Darras BT, De Vivo DC, Finkel R, Muntoni F, Mercuri E. Revised upper limb module for spinal muscular atrophy: Development of a new module. //Muscle Nerve. V. 55(6) P.869-874. doi: 10.1002/mus.25430. Epub 2017 Feb 6.
  40. Li L., Zhou W.J., Fang P. et al. Evaluation and comparison of three assays for molecular detection of spinal muscular atrophy. //Clin Chem Lab Med. 2017, V. 1;55(3) P.358-367.
  41. Jin Y.W., Qu Y.J., Wang H. et al. Limitation of PCR-RFLP method for the detection of genetic mutations in spinal muscular atrophy. // Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2012 V. 29(1) P. 34-7.
  42. Yang L., Cao Y.Y., Qu Y.J. et al. Sanger sequencing for the diagnosis of spinal muscular atrophy patients with survival motor neuron gene 1 compound heterozygous mutation. // Zhonghua Yi Xue Za Zhi. 2017 V. 97(6) P. 418-423
  43. Yinhong Zhang, Jing He , Yunqian Zhang, Li Li, Xinhua Tang, Lei Wang, Jingjing Guo, Chanchan Jin, Sean Tighe, Yuan Zhang, Yingting Zhu, Baosheng Zhu The Analysis of the Association Between the Copy Numbers of Survival Motor Neuron Gene 2 and Neuronal Apoptosis Inhibitory Protein Genes and the Clinical Phenotypes in 40 Patients With Spinal Muscular Atrophy: Observational Study Medicine (Baltimore) 2020 Jan;99(3):e18809.doi: 10.1097/MD.0000000000018809.
  44. MacDonald W.K., Hamilton D., Kuhle S. SMA carrier testing: a meta-analysis of differences in test performance by ethnic group. // Prenat Diagn. 2014 V. 34(12) P. 1219­26.
  45. Rudnik-Schoneborn S., Lutzenrath S., Borkowska J. Analysis of creatine kinase activity in 504 patients with proximal spinal muscular atrophy types I-III from the point of view of progression and severity. // Eur Neurol. 1998 V. 39(3) P. 154-62.
  46. Bersanini C1, Khirani S, Ramirez A, Lofaso F, Aubertin G, Beydon N, Mayer M, Maincent K, Boule M, Fauroux B. Nocturnal hypoxaemia and hypercapnia in children with neuromuscular disorders. // Eur Respir J. 2012, V. 39(5) P.1206-12. doi: 10.1183/09031936.00087511. Epub 2011 Dec 1.
  47. 0rngreen MC, Zacho M, Hebert A et al. Patients with severe muscle wasting are prone to develop hypoglycemia during fasting. // Neurology. 2003 V. 61(7) P. 997-1000.
  48. Hausmanowa-Petrusewicz I., Karwanska A. Electromyographic findings in different forms of infantile and juvenile proximal spinal muscular atrophy. // Muscle Nerve. 1986 V. 9(1) P. 37-46.
  49. Bromberg MB1, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy.// Muscle Nerve. 2002, V.25(3) P.445-7.
  50. Oudeman J, Eftimov F, Strijkers GJ, Schneiders JJ, Roosendaal SD, Engbersen MP, Froeling M, Goedee HS, van Doorn PA, Caan MWA, van Schaik IN, Maas M, Nederveen AJ, de Visser M, Verhamme C. Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. //Neurology. 2020, V.7;94(1):e62- e74. doi: 10.1212/WNL.0000000000008697. Epub 2019 Dec 11.
  51. Zalneraitis E.L., Halperin J.J., Grunnet M.L. et al. Muscle biopsy and the clinical course of infantile spinal muscular atrophy. // J Child Neurol. 1991 V. 6(4) P. 324-8.
  52. Wijngaarde C. A., Blank A. C., Stam M. et al. Cardiac pathology in spinal muscular atrophy: a systematic review. // Orphanet J Rare Dis. 2017 V. 12 P. 67.
  53. Palladino A, Passamano L, Taglia A, D'Ambrosio P, Scutifero M, Cecio MR, Picillo E, Viggiano E, Torre V, De Luca F, Nigro G, Politano L. Cardiac involvement in patients with spinal muscular atrophies. //Acta Myol. 2011, V.30(3) P.175-8.
  54. Wasserman H.M., Hornung L.N., Stenger P.J. Rutter M.M. Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity. // Neuromuscul Disord. 2017 Apr; 27(4): 331—337.doi: 10.1016/j.nmd.2017.01.019
  55. Vai S., Bianchi M.L., Moroni I. et al. Bone and Spinal Muscular Atrophy. // Bone. 2015 V. 79 P. 116-20.
  56. Chua K., Tan C.Y., Chen Z. et al. Long-term Follow-up of Pulmonary Function and Scoliosis in Patients With Duchenne's Muscular Dystrophy and Spinal Muscular Atrophy. // J Pediatr Orthop. 2016 V. 36(1) P. 63-9
  57. Finkel R.S., Mercuri E., Meyer O.H. et al; SMA Care group. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. // Neuromuscul Disord. 2018 V. 28(3) P. 197-207
  58. Cherry J.J., Kobayashi D.T., Lynes M.M., et al. Assays for the identification and prioritization of drug candidates for spinal muscular atrophy. // Assay Drug Dev Technol. 2014 V. 12 P. 315-41.
  59. Pattali R., Mou Y., Li XJ. AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. // Gene Therapy. 2019. V. 26, P 287-295
  60. Dangouloff T., Servais L. Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. // Ther Clin Risk Manag. 2019 V. P. 1153­1161.
  61. Finkel R.S., Mercuri E., Darras B.T. et al; ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. // N Engl J Med. 2017 V. 377(18) P. 1723-1732.
  62. Servais, L.; Baranello, G.; Masson, R.; et al. FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA) 2020; NEUROLOGY; Volume: 94 Issue: 15 Supplement: S Meeting Abstract: 1302http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=Gen eralS earch& qid=3&SID=C3tnfn4Grw 1fI1vmPpP&page= 1 & doc=2
  63. Mercuri E., Darras B.T., Chiriboga C.A., Day J.W., Campbell C., Connolly A.M., and R.S. Finkel. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.2018; 378 (7):625-635
  64. Darras B.T. , Chiriboga C.A. , Iannaccone S.T., Swoboda K.J. , Montes J., Mignon L. et al. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies. Neurology; 2019 May 21;92(21):e2492-e250 doi: 10.1212/WNL.0000000000007527.
  65. Mercuri, E ; Barisic, N; Boespflug-Tanguy, O ; Deconinck, N ; Kostera-Pruszczyk, ; Masson, R ; Mazzone, E ; Nascimento, A ; Saito, K ; Vlodavets, D (Vlodavets, Dmitry) et al. SUNFISH Part 2: Efficacy and safety of risdiplam (RG7916) in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA) Annual Meeting of the American- Academy-of-Neurology Toronto, CANADA Date: APR 25-MAY 01, 2020 NEUROLOGY Volume: 94 Issue: 15 Supplement: S Meeting Abstract: 126
  66. De Vivo D.C., Bertini E., Swoboda K.J. et al; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. // Neuromuscul Disord. 2019 V. 29(11) P. 842-856.
  67. Glascock J., Sampson J., Haidet-Phillips A. et al. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening. // J Neuromuscul Dis. 2018 V. 5(2) P. 145-158.
  68. Aton J., Davis R.H., Jordan K.C. et al. Vitamin D intake is inadequate in spinal muscular atrophy type I cohort: correlations with bone health. // J Child Neurol. 2014 V. 29(3), P. 374-380
  69. Shoval H.A., Antelis E., Hillman A., et al. Onabotulinum Toxin A Injections Into the Salivary Glands for Spinal Muscle Atrophy Type I: A Prospective Case Series of 4 Patients. // Am J Phys Med Rehabil. 2018 V. 97(12)P . 873-878.
  70. McGeachan A.J., Mcdermott C.J.: Management of oral secretions in neurological disease. // Pract Neurol 2017 V. 17 P. 96-103
  71. McElroy M.J., Shaner A.C., Crawford T.O., et al. Growing rods for scoliosis in spinal muscular atrophy: structural effects, complications, and hospital stays. // Spine. 2011 V. 36(16) P. 1305-1311
  72. Fujak A, Raab W, Schuh A, Kress A, Forst R, Forst J. Operative treatment of scoliosis in proximal spinal muscular atrophy: results of 41 patients. //Arch Orthop Trauma Surg .2012, V.132(12) P.1697-706
  73. Livingston K., Zurakowski D., Snyder B., Growing Spine Study Group, Children's Spine Study Group. Parasol rib deformity in hypotonic neuromuscular scoliosis: a new radiographical definition and a comparison of short-term treatment outcomes with VEPTR and growing rods. // Spine 2015, V. 40 (13), P. E780-E786
  74. Bamerias C., Quijano S., Mayer M., et al. Multicentric study of medical care and practices in spinal muscular atrophy type 1 over two 10-year periods. //Arch Pediatr. 2014, V. 21(4) P. 347-54.
  75. Durkin ET, Schroth MK, Helin M, Shaaban AF. Early laparoscopic fundoplication and gastrostomy in infants with spinal muscular atrophy type I. //J Pediatr Surg. 2008 V. 43(11) P.2031-7
  76. Simonds A.K. Home Mechanical Ventilation: An Overview. // Ann Am Thorac Soc. 2016 V. 13(11) P. 2035-2044.
  77. Moore G.E., Lindenmayer A.W., McConchie G.A., et al. Describing nutrition in spinal muscular atrophy: A systematic review. // Neuromuscul Disord. 2016 V. 26(7) P. 395-404.
  78. Schofield C. An annotated bibliography of source material for basal metabolic rate data. Hum Nutr Clin Nutr 1985;39 (Suppl. 1):42—91].
  79. Stoimenis D, Spyridonidou C, Theofanidou S, Petridis N, Papaioannou N, Iasonidou C, Kapravelos N. Euglycemic Ketoacidosis in Spinal Muscular Atrophy. // Case Rep Pediatr. 2019 V. 27;2019:2862916. doi: 10.1155/2019/2862916. eCollection 2019.
  80. Davis RH, Godshall BJ, Seffrood E, Marcus M, LaSalle BA, Wong B, et al. Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings. //J Child Neurol.2014, V.29(11) P.1467-72.
  81. Sepulveda C., Marlin A., Yoshida T., Ullrich A. Palliative care: the World Health Organization’s global perspective. // J Pain Symptom Manage. 2002; V.24 P. 91-96
  82. Pastrana T., Junger S., Ostgathe C., Elsner F, Radbruch L.. A matter of definition - key elements identified in a discourse analysis of definitions of palliative care. // Palliat Med 2008 V. 22 P. 222- 232
  83. Wang C.H., Finkel R.S., Bertini E.S., et al. Consensus statement for standard of care in spinal muscular atrophy. // J Child Neurol 2007 V. 22(8) P. 1027-49. doi:10.1177/0883073807305788
  84. Bach J.R. Medical considerations of long-term survival of Werdnig-Hoffmann disease. // Am J Phys Med Rehabil 2007 V. 86 P. 349-55.
  85. Garcia-Salido A, de Paso-Mora M.G., Monleon-Luque M., Martino-Alba R. Palliative care in children with spinal muscular atrophy type I: what do they need? // Palliat Support Car 2015 V. 13 P. 313-17
  86. Hull J., Aniapravan R., E.Chan et al. (2012). Guidelines for respiratory management of children with neuromuscular weakness British Thoracic Society Respiratory Management of Children with Neuromuscular Weakness Guideline Group // Thorax, 2012 V. 67 S. 1. - i1 - i40
  87. Geevasinga N., Ryan M.M. Physician attitudes towards ventilator support for spinal muscular atrophy type1 in Australasia. // J Paediatrics Child Health, 2007; V. 43 P. 790­794.
  88. Hardart M.K., Burns J.P., Truog R.D. Respiratory support in spinal muscular atrophy type 1: a survey of physician practices and attitudes. // Pediatrics, 2002 V. 110 P. e24.
  89. Dybwik K., Tollali T., Nielsen E.W. et al. Why does the provision of home mechanical ventilation vary so widely? // Chronic Respir Dis, 2010 V. 7 P. 67-73.
  90. Mah J.K., Thannhauser J.E., Kolski H. et al. Parental stress and quality of life in children with neuromuscular disease. // Pediatr Neurol, 2008 V. 39 P. 102-107.
  91. Engel J. M., Karlin D., Carter G. T., Jensen M. P., Jaffe K. M. Pain in youths with neuromuscular disease. //American Journal of Hospice and Palliative Medicine. 2009 V.26(5) P. 405-412. doi: 10.1177/1049909109346165
  92. Dunaway S, Montes J, McDermott MP, Martens W, Neisen A, Glanzman AM, Pasternak A, Riley S, Sproule D, Chiriboga C, Finkel R, Tennekoon G, Darras B, De Vivo D, Pandya S Physical therapy services received by individuals with spinal muscular atrophy (SMA).// J Pediatr Rehabil Med. 2016; V.9(1) P.35-44. doi: 10.3233/PRM-160360.
  93. Cunha M.C., Oliveira A.C., Labronici R.H., Gabbai A.A. Spinal Muscular Atrophy Type II (Intermediary) and III (Kugelberg-Welander). Evolution of 50 Patients With Physiotherapy and Hydrotherapy in a Swimming Pool. // Arq Neuropsiquiatr. 1996 V.54(3), P.402-6. doi: 10.1590/s0004-282x 1996000300007.
  94. Keefe F.J., Surwit R.S. Electromyographic biofeedback: behavioral treatment of neuromuscular disorders. // J Behav Med. 1978 V. 1(1) P. 13-24.
  95. Kelle B., Tas D., Erkan D. Kinesio taping application in a pediatric patient with spinal muscular atrophy. // Cukurova Medical Journal. 2016 V. 41 P. 386-389.
  96. Fujak A., Kopschina C., Forst R., et al. Use of orthoses and orthopaedic technical devices in proximal spinal muscular atrophy. Results of survey in 194 SMA patients. // Disabil Rehabil Assist Technol 2011 V. 6(4) P. 305-11.
  97. Demir Y.P.. Neuromuscular Diseases and Rehabilitation. // Neurological Physical Therapy, 2017, P. 176-214
  98. Luc M, Bensoussan L, Viton JM, de Bovis VM, Collado H, Pouget J, Delarque A.J a patellar tendon-bearing orthosis and orthopaedic shoes. Gait recovery in a distal spinal muscular atrophy patient wearing a patellar tendon-bearing orthosis and orthopedic shoes//Rehabil Med. 2007, V.39(2) P.181-4. doi: 10.2340/16501977-0025.
  99. Subasi S., Yildiz T.I., Bulut N.et al. G.P.243: Orthosis usage and ambulation levels in different clinical types of SMA. // Neuromuscul Disord 2014 V. 24(9-10) P. 889-890
  100. Dunaway S., Montes J., O'Hagen J.et al. Independent mobility after early introduction of a power wheelchair in spinal muscular atrophy. // J Child Neurol, 2013 V. 28 (5), P. 576-582
  101. Инструкция по медицинскому применению препарата Золгенсма® (раствор для инфузий). Регистрационное удостоверение номер ЛП-007675 от 09.12.2021 г. Государственный реестр лекарственных средств, https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=57a4c3e1-4577-4435-b3b0- 5dfbfc3ff2ec&t=
  102. Al-Zaidy S.A., Mendell J.R. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr. Neurol. 2019; 100: 3­11. https://doi.org/10.1016/j.pediatrneurol.2019.06.007
  103. https://www.fda.gov/news-events/press-announcements/fda-approves-innovative- gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease
  104. https://www.novartis.com/news/media-releases/avexis-receives-positive-chmp- opinion-zolgensma-only-gene-therapy-spinal-muscular-atrophy-sma
  105. Mercuri E., Muntoni F., Baranello G. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open- label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021 Oct;20(10):832-841. doi: 10.1016/S1474-4422(21)00251 -9.
  106. Mendell J.R., Al-Zaidy S., Shell R. et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2;377(18):1713-1722. doi: 10.1056/NEJMoa1706198.
  107. Day J.W., Finkel R.S., Chiriboga C.A. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021 Apr;20(4):284-293. doi: 10.1016/S1474-4422(21)00001-6. Epub 2021 Mar 17
  108. Kirschner J., Butoianu N., Goemans N. et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur. J. Paediatr. Neurol. 2020; 28: 38-43. https://doi.org/10.1016/j.ejpn.2020.07.001
  109. Strauss K. et al. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 2 Copies of SMN2 (4190). Neurology, April 13, 2021; 96 (15 Supplement), https://n.neurology.org/content/96/15_Supplement/4190.
  110. Strauss K. et al. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 3 Copies of SMN2 (4163). Neurology, April 13, 2021; 96 (15 Supplement), https://n.neurology.org/content/96/15_Supplement/4163.
  111. Wan, B., Feng, P., Guan, Z., et al. (2018). A severe mouse model of spinal muscular atrophy develops early systemic inflammation. Human molecular genetics, 27(23), 4061­4076. https://doi.org/10.1093/hmg/ddy300
  112. Deguise MO, Chehade L, Kothary R. Metabolic Dysfunction in Spinal Muscular Atrophy. Int J Mol Sci. 2021;22(11):5913. Published 2021 May 31. doi:10.3390/ijms22115913
  113. Djordjevic SA, Milic-Rasic V, Brankovic V, et al. Glucose and lipid metabolism disorders in children and adolescents with spinal muscular atrophy types 2 and 3. Neuromuscul Disord. 2021;31(4):291-299. doi:10.1016/j.nmd.2021.02.002
  114. Alves CRR, Zhang R, Johnstone AJ, et al. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. Neurology. 2020;94(9):e921-e931. doi:10.1212/WNL.0000000000008762
  115. Nery FC, Siranosian JJ, Rosales I, et al. Impaired kidney structure and function in spinal muscular atrophy. Neurol Genet. 2019;5(5):e353. Published 2019 Aug 12. doi:10.1212/NXG.0000000000000353
  116. Wijngaarde CA, Huisman A, Wadman RI, et al. Abnormal coagulation parameters are a common non-neuromuscular feature in patients with spinal muscular atrophy. Journal of Neurology, Neurosurgery & Psychiatry 2020; 91:212-214.
  117. Saffari, A., Cannet, C., Blaschek, A. et al. 1H-NMR-based metabolic profiling identifies non-invasive diagnostic and predictive urinary fingerprints in 5q spinal muscular atrophy. Orphanet J Rare Dis 16, 441 (2021). https://doi.org/10.1186/s13023-021-02075-x
  118. Жданова Л.В., Лебедева О.А., Колмакова В.В., Русинова Т.А. Развитие амбулаторной паллиативной помощи детям и подросткам в Республике Бурятия // Вестник Бурятского государственного университета. Медицина и фармация. 2019БыпЛ.С.39-43.
  119. Минаева Н.В., Исламова Р.И., Баженова М.И. Выездная патронажная паллиативная медицинская помощь детям: двухлетний опыт работы некоммерческой благотворительной организации // «Вопросы современной педиатрии». 2020; 19(1): 46-56.
  120. Соколова М.Г., Никишина О.А. Использование искусственной вентиляции легких у тяжелобольных детей в домашних условиях // «Здоровье - основа человеческого потенциала: проблемы и пути их решения». - 2013. Том №8, №1. - С. 262-263
  121. Исламова Р.И., Порхачева Ю.А., Минаева Н.В. Организация респираторной поддержки паллиативному пациенту со спинальной мышечной атрофией // «Актуальные вопросы педиатрии». Материалы краевой научно-практической конференции, посвященной памяти профессора И.П.Корюкиной. Пермь, 2021. - с 71­75
  122. Ryabykh SO, Savin DM, Filatov EYu et al. Spinal muscular atrophy: clinical features and treatment of spinal and limb deformities. Interstate Consensus Protocol. Hir. Pozvonoc. 2020;17(2):79-94. In Russian. DOI: http://dx.doi.org/10.14531/ss2020.2.79-94
  123. Smith G, Bell SK, Sladky JT et al. Lumbosacral ventral spinal nerve root atrophy identified on MRI in a case of spinal muscular atrophy type II. Clin Imaging. 2019; 53:134­137. doi: 10.1016/j.clinimag.2018.09.017
  124. Veiga-Canuto D, Cifrian-Perez M, Pitarch-Castellano I et al. Ultrasound-guided lumbar puncture for nusinersen administration in spinal muscular atrophy patients. Eur JNeurol. 2021;28(2):676-680. doi:10.1111/ene.14586
  125. Gerlinger I, Szalai G, Hollody K, Nemeth A. Ultrasound-guided, intraglandular injection of botulinum toxin A in children suffering from excessive salivation. J Laryngol Otol. 2007;121(10):947-951. doi:10.1017/S0022215107006949.
  126. Cichocki P, Zyzniewska-Banaszak E, Mosiejczuk H. Strategia fizjoterapii u chorych z dysfagia z powodu rdzeniowego zaniku miesni typu Ib. Studium przypadku [Strategy of physiotherapy in dysphagia associated with spinal muscular atrophy type Ib: Case study]. Ann Acad Med Stetin. 2011;57(1):26-30.
  127. Шаймурзин М.Р., Луцкий И.С. Спинальные мышечные атрофии: от современных возможностей к новой стратегии оказания помощи. Кубанский научный медицинский вестник. 2020;27(6):80-93. https://doi.org/10.25207/1608-6228-2020-27- 6-80-93
  128. van Bruggen H.W., Wadman R.I., Bronkhorst E.M. et al. Mandibular dysfunction as a reflection of bulbar involvement in SMA type 2 and 3. Neurology. 2016 Feb 9;86(6):552- 9. doi: 10.1212/WNL.0000000000002348. Epub 2016 Jan 13. PMID: 26764025.
  129. Wadman R.I., van Bruggen H.W., Witkamp T.D. et al. Bulbar muscle MRI changes in patients with SMA with reduced mouth opening and dysphagia. Neurology. 2014 Sep 16;83(12):1060-6. doi: 10.1212/WNL.0000000000000796. Epub 2014 Aug 13. PMID: 25122201.
  130. Lee S, Lee YJ, Kong J, et al. Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy. Brain Dev. 2022;44(4):287-293. doi: 10.1016/j.braindev.2021.12.006
  131. Ropars J, Peudenier S, Genot A, Barnerias C, Espil C. Multidisciplinary approach and psychosocial management of spinal muscular atrophy (SMA). Arch Pediatr. 2020;27(7S):7S45-7S49. doi:10.1016/S0929-693X(20)30277-3
  132. Strauss KA,      Farrar MA, Muntoni         F,    et al.     Onasemnogene      abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381-1389. doi:10.1038/s41591-022- 01866-4
  133. Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1390-1397. doi:10.1038/s41591-022-01867- 3
  134. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842-856. doi:10.1016/j.nmd.2019.09.007
  135. Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening. J Neuromuscul Dis. 2018;5(2):145-158. doi:10.3233/JND-180304
  136. Matesanz SE, Curry C, Gross B, et al. Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec. J Child Neurol. 2020;35(11):717-723. doi:10.1177/0883073820928784
  137. Axelson T, Willard A, Jain K1117 Survey of physician practice and opinions regarding the use of palivizumab as RSV prophylaxis, including in children with SMA Type 1Archives of Disease in Childhood 2022;107:A246. http://dx.doi.org/10.1136/archdischild- 2022-rcpch.396
  138. Bitetti I, Lanzara V, Margiotta G, Varone A. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study [published online ahead of print, 2022 May 24]. Gene Ther. 2022;10.1038/s41434-022-00341 -6. doi:10.1038/s41434-022-00341 -6
  139. Sansone VA, Racca F, Ottonello G, et al. 1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015. Neuromuscul Disord. 2015;25(12):979-989. doi: 10.1016/j.nmd.2015.09.009

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*